These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 30552833)

  • 1. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
    Desai RJ; Pawar A; Weinblatt ME; Kim SC
    Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.
    Desai RJ; Pawar A; Khosrow-Khavar F; Weinblatt ME; Kim SC
    Rheumatology (Oxford); 2021 Dec; 61(1):121-130. PubMed ID: 33752237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
    Charles-Schoeman C; Fleischmann R; Mysler E; Greenwald M; Ytterberg SR; Koch GG; Bhatt DL; Wang C; Mikuls TR; Chen AS; Connell CA; Woolcott JC; Menon S; Chen Y; Lee K; Szekanecz Z
    Arthritis Rheumatol; 2024 Aug; 76(8):1218-1229. PubMed ID: 38481002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F; Yun H; Bernatsky S; Curtis JR
    Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
    Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
    Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study.
    Desai RJ; Gagne JJ; Lii J; Liu J; Friedman S; Kim SC
    CMAJ; 2017 Nov; 189(47):E1438-E1447. PubMed ID: 29180383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
    Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
    Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
    Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
    Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study.
    Li L; Lu N; Avina-Galindo AM; Zheng Y; Lacaille D; Esdaile JM; Choi HK; Aviña-Zubieta JA
    Rheumatology (Oxford); 2021 Jan; 60(1):188-195. PubMed ID: 32617563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
    Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S
    Aliment Pharmacol Ther; 2019 Nov; 50(10):1068-1076. PubMed ID: 31599001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
    Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
    Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
    Song YJ; Cho SK; Kim JY; You SH; Kim H; Jung SY; Sung YK
    Semin Arthritis Rheum; 2023 Aug; 61():152214. PubMed ID: 37172496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.
    Khosrow-Khavar F; Desai RJ; Lee H; Lee SB; Kim SC
    Arthritis Rheumatol; 2022 Oct; 74(10):1648-1659. PubMed ID: 35643956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.